Listing on the Pharmaceutical Schedule of a range of orthopaedic implants and associated products with LMT Surgical Pty Ltd

5 April 2017 - PHARMAC is pleased to announce the approval of a listing agreement for the supply of orthopaedic ...

Read more →

Proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) in the Hospital medicines list

31 March 2017 - PHARMAC is seeking feedback on a proposal to list 5-aminolevulinic acid hydrochloride (Gliolan) through a provisional ...

Read more →

Proposal to list a range of orthopaedic implants and associated products supplied by LMT Surgical Pty Ltd

9 March 2017 - PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated ...

Read more →

Additional listings on the Pharmaceutical Schedule of a range of orthopaedic implants and associated products with Smith and Nephew Limited

27 February 2017 - PHARMAC is pleased to announce the approval of an amendment to the trauma agreement with Smith ...

Read more →

Proposal to list orthopaedic hip and knee implants, cement and associated products on the Pharmaceutical Schedule

2 February 2017 - PHARMAC is seeking feedback on a proposal to list further ranges of orthopaedic implants and associated ...

Read more →

Proposal to maintain full subsidy for gefitinib (Iressa) from 1 April 2017

20 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of funding for gefitinib ...

Read more →

Proposal to list a range of orthopaedic implants and associated products supplied by Zimmer Biomet New Zealand

16 December 2016 - PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated ...

Read more →

Proposal to amend listings in the National Immunisation Schedule

9 December 2016 - Following a request for proposals for the supply of various vaccines, issued on 15 February 2016, ...

Read more →

Proposal to list oral betaine for rare disorder

16 November 2016 - PHARMAC is seeking feedback on a proposal to list betaine (Cystadane) resulting from a provisional agreement ...

Read more →

Proposal to list and award sole supply to celecoxib Pfizer

31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class ...

Read more →

Update on proposed changes to 2nd & 3rd line anti-VEGF treatments for ophthalmic use

28 October 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...

Read more →

Proposal relating to two HIV treatments (Tivicay and Kivexa)

9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...

Read more →

Proposal related to second & third-line anti-VEGF treatments for ophthalmic use

5 September 2016 - PHARMAC has entered into provisional agreements with Novartis and Bayer and is seeking feedback on a ...

Read more →

Proposal to award sole supply of venlafaxine hydrochloride

10 August 2016 - PHARMAC is seeking feedback on a proposal to award sole supply status in the community for venlafaxine hydrochloride ...

Read more →

Over 100,000 people set to benefit from PHARMAC vaccines decisions

28 July 2016 - PHARMAC has today announced changes to funded vaccines, which will benefit an extra 100,000 people. ...

Read more →